This HTML5 document contains 75 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n4http://www.rxlist.com/cgi/generic3/
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n6http://linked.opendata.cz/resource/drugbank/company/
n25http://linked.opendata.cz/resource/mesh/concept/
foafhttp://xmlns.com/foaf/0.1/
n23http://linked.opendata.cz/resource/drugbank/drug/DB00232/identifier/pharmgkb/
n8http://linked.opendata.cz/resource/drugbank/dosage/
n14http://linked.opendata.cz/resource/drugbank/drug/DB00232/identifier/kegg-compound/
n18http://linked.opendata.cz/resource/drugbank/drug/DB00232/identifier/pubchem-compound/
n22http://bio2rdf.org/drugbank:
n19http://linked.opendata.cz/resource/drugbank/drug/DB00232/identifier/pubchem-substance/
admshttp://www.w3.org/ns/adms#
n15http://linked.opendata.cz/resource/drugbank/drug/DB00232/identifier/kegg-drug/
n10http://linked.opendata.cz/resource/drugbank/drug/DB00232/identifier/drugbank/
n17http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n13http://linked.opendata.cz/resource/drugbank/medicinal-product/
n12http://linked.opendata.cz/resource/drugbank/drug/DB00232/identifier/national-drug-code-directory/
owlhttp://www.w3.org/2002/07/owl#
n24http://linked.opendata.cz/ontology/mesh/
n5http://linked.opendata.cz/ontology/drugbank/
n21http://www.drugs.com/cdi/
n7http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n11http://linked.opendata.cz/resource/drugbank/drug/DB00232/identifier/chemspider/
n27http://linked.opendata.cz/resource/atc/
n26http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00232
rdf:type
n5:Drug
n5:description
A thiazide diuretic with properties similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p825)
n5:dosage
n8:271B61DB-363D-11E5-9242-09173F13E4C5
n5:group
approved
n5:indication
For use in the management of hypertension either as the sole therapeutic agent or to enhance the effect of other antihypertensive drugs in the more severe forms of hypertension. Also used as adjunctive therapy in edema associated with congestive heart failure, hepatic cirrhosis, and corticosteroid and estrogen therapy.
n5:manufacturer
n6:271B61D1-363D-11E5-9242-09173F13E4C5 n6:271B61D2-363D-11E5-9242-09173F13E4C5 n6:271B61D0-363D-11E5-9242-09173F13E4C5 n6:271B61D5-363D-11E5-9242-09173F13E4C5 n6:271B61D6-363D-11E5-9242-09173F13E4C5 n6:271B61D3-363D-11E5-9242-09173F13E4C5 n6:271B61D4-363D-11E5-9242-09173F13E4C5 n6:271B61D7-363D-11E5-9242-09173F13E4C5
owl:sameAs
n17:DB00232 n22:DB00232
dcterms:title
Methyclothiazide
adms:identifier
n10:DB00232 n11:3978 n12:0378-0160-01 n14:C07765 n15:D00656 n18:4121 n19:46509197 n23:PA164748094
n5:mechanismOfAction
Methyclothiazide appears to block the active reabsorption of chloride and possibly sodium in the ascending loop of Henle, altering electrolyte transfer in the proximal tubule. This results in excretion of sodium, chloride, and water and, hence, diuresis. As a diuretic, methyclothiazide inhibits active chloride reabsorption at the early distal tubule via the Na-Cl cotransporter, resulting in an increase in the excretion of sodium, chloride, and water. Thiazides like methyclothiazide also inhibit sodium ion transport across the renal tubular epithelium through binding to the thiazide sensitive sodium-chloride transporter. This results in an increase in potassium excretion via the sodium-potassium exchange mechanism. The antihypertensive mechanism of methyclothiazide is less well understood although it may be mediated through its action on carbonic anhydrases in the smooth muscle or through its action on the large-conductance calcium-activated potassium (KCa) channel, also found in the smooth muscle.
n5:packager
n6:271B61CD-363D-11E5-9242-09173F13E4C5 n6:271B61CE-363D-11E5-9242-09173F13E4C5 n6:271B61CB-363D-11E5-9242-09173F13E4C5 n6:271B61CC-363D-11E5-9242-09173F13E4C5 n6:271B61C9-363D-11E5-9242-09173F13E4C5 n6:271B61CA-363D-11E5-9242-09173F13E4C5 n6:271B61CF-363D-11E5-9242-09173F13E4C5
n5:synonym
Enduron
n5:toxicity
Acute oral toxicity (LD<sub>50</sub>): >4000 mg/kg [Rat]. Symptoms of overdosage include electrolyte imbalance and signs of potassium deficiency such as confusion, dizziness, muscular weakness, and gastrointestinal disturbances.
n24:hasConcept
n25:M0013609
foaf:page
n4:methyclothiazide.htm n21:methyclothiazide.html
n5:IUPAC-Name
n7:271B61E0-363D-11E5-9242-09173F13E4C5
n5:InChI
n7:271B61E6-363D-11E5-9242-09173F13E4C5
n5:Molecular-Formula
n7:271B61E5-363D-11E5-9242-09173F13E4C5
n5:Molecular-Weight
n7:271B61E2-363D-11E5-9242-09173F13E4C5
n5:Monoisotopic-Weight
n7:271B61E3-363D-11E5-9242-09173F13E4C5
n5:SMILES
n7:271B61E4-363D-11E5-9242-09173F13E4C5
n5:Water-Solubility
n7:271B61DE-363D-11E5-9242-09173F13E4C5 n7:271B61F6-363D-11E5-9242-09173F13E4C5
n5:logP
n7:271B61DF-363D-11E5-9242-09173F13E4C5 n7:271B61F8-363D-11E5-9242-09173F13E4C5 n7:271B61DC-363D-11E5-9242-09173F13E4C5
n5:logS
n7:271B61DD-363D-11E5-9242-09173F13E4C5
n5:pKa
n7:271B61F9-363D-11E5-9242-09173F13E4C5
n26:hasATCCode
n27:C03AA08
n5:H-Bond-Acceptor-Count
n7:271B61EC-363D-11E5-9242-09173F13E4C5
n5:H-Bond-Donor-Count
n7:271B61ED-363D-11E5-9242-09173F13E4C5
n5:InChIKey
n7:271B61E7-363D-11E5-9242-09173F13E4C5
n5:Polar-Surface-Area--PSA-
n7:271B61E8-363D-11E5-9242-09173F13E4C5
n5:Polarizability
n7:271B61EA-363D-11E5-9242-09173F13E4C5
n5:Refractivity
n7:271B61E9-363D-11E5-9242-09173F13E4C5
n5:Rotatable-Bond-Count
n7:271B61EB-363D-11E5-9242-09173F13E4C5
n5:absorption
Rapidly absorbed following oral administration.
n5:affectedOrganism
Humans and other mammals
n5:casRegistryNumber
135-07-9
n5:category
n5:containedIn
n13:271B61DA-363D-11E5-9242-09173F13E4C5 n13:271B61D8-363D-11E5-9242-09173F13E4C5 n13:271B61D9-363D-11E5-9242-09173F13E4C5
n5:Bioavailability
n7:271B61F2-363D-11E5-9242-09173F13E4C5
n5:Ghose-Filter
n7:271B61F4-363D-11E5-9242-09173F13E4C5
n5:MDDR-Like-Rule
n7:271B61F5-363D-11E5-9242-09173F13E4C5
n5:Melting-Point
n7:271B61F7-363D-11E5-9242-09173F13E4C5
n5:Number-of-Rings
n7:271B61F1-363D-11E5-9242-09173F13E4C5
n5:Physiological-Charge
n7:271B61F0-363D-11E5-9242-09173F13E4C5
n5:Rule-of-Five
n7:271B61F3-363D-11E5-9242-09173F13E4C5
n5:Traditional-IUPAC-Name
n7:271B61E1-363D-11E5-9242-09173F13E4C5
n5:pKa--strongest-acidic-
n7:271B61EE-363D-11E5-9242-09173F13E4C5
n5:pKa--strongest-basic-
n7:271B61EF-363D-11E5-9242-09173F13E4C5